 |
| Original article |
| Homozygous deletions at 3p12 in breast and lung cancer |
|
| Vasi Sundaresan1, Grace Chung1, Amanda Heppell-Parton1, J Xiong1, Catherine Grundy2, Ian Roberts1, Louise James2, Anthony Cahn1, Anthony Bench1, Jenny Douglas1, John Minna3, Yoshitaka Sekido3, Michael Lerman4, Farida Latif4, Jonas Bergh5, Hua Li4, Nick Lowe1, Donald Ogilvie2 and Pamela Rabbitts1,a |
|
1Medical Research Council Centre, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
2ZENECA Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
3Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas 75235-8593 USA
4Laboratory of Immunobiology, National Cancer Institute, Frederick Cancer Research Facility, Bldg. 560, Room 12-25, Frederick, Maryland 21701 USA
5Department of Oncology, University of Uppsala, Akademiska Sjukhuset, S-751 85 Uppsala, Sweden
|
|
aAuthor for correspondence |
|
| Abstract |
| We have constructed a physical map of the region homozygously deleted in the U2020 cell line at 3p12, including the location of putative CpG islands. Adjacent to one of these islands, we have identified and cloned a new gene (DUTT1) and used probes from this gene to detect two other homozygous deletions occurring in lung and breast carcinomas: the smallest deletion is within the gene itself and would result in a truncated protein. The DUTT1 gene is a member of the neural cell adhesion molecule family, although its widespread expression suggests it plays a less specialized role compared to other members of the family. |
|
| Keywords |
| DUTT1/Hrobo-1; lung cancer; U2020 deletion; tumour suppressor gene; familial non-specific dementia |
|
|
|
|
| Received 6 March 1998; revised 5 May 1998; accepted 5 May 1998 |
|
| 1 October 1998, Volume 17, Number 13, Pages 1723-1729 |
| Table of contents Previous Abstract Next Article PDF |
|
